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Objective: The study we assessed how often patients who are manifesting a myocardial infarction (MI)
would not be considered candidates for intensive lipid-lowering therapy based on the current guidelines.
Methods: In 355 consecutive patients manifesting ST elevation MI (STEMI), admission plasma C-reactive
protein (CRP) was measured and Framingham risk score (FRS), PROCAM risk score, Reynolds risk score,
ASSIGN risk score, QRISK, and SCORE algorithmswere applied. Cardiac computed tomography and carotid
ultrasound were performed to assess the coronary artery calcium score (CAC), carotid intima-media
thickness (cIMT) and the presence of carotid plaques.
Results: Less than 50% of STEMI patients would be identiﬁed as having high risk before the event by any
of these algorithms. With the exception of FRS (9%), all other algorithms would assign low risk to about
half of the enrolled patients. Plasma CRP was <1.0mg/L in 70% and >2mg/L in 14% of the patients. Thearotid intima-media thickness average cIMT was 0.8±0.2mm and only in 24% of patients was ≥1.0mm. Carotid plaques were found in
74% of patients. CAC ≥100 was found in 66% of patients. Adding CAC ≥100 plus the presence of carotid
plaque, a high-risk conditionwould be identiﬁed in 100%of thepatients using anyof the abovementioned
algorithms.
Conclusion: More than half of patients manifesting STEMI would not be considered as candidates for
intensive preventive therapy by the current clinical algorithms. The addition of anatomical parameters
nce osuch as CAC and the prese
. Introduction
Clinicians have been concerned with how to assign properly
he risk of cardiovascular disease (CVD) in the setting of targets
or primary prevention. Indeed, recently, a signiﬁcant reduction in
VD mortality was obtained by intensive lipid-lowering treatment
n individuals a priori not considered candidates for such therapy
ccording to the traditional risk estimation and to current guide-
ines [1]. In that trial, the use of elevated levels of C-reactive protein
CRP) as inclusion criterion could have helped to select patients at
nhanced risk. However, the study design did not allow to verify if
ndividuals who were not enrolled because of their low CRP were
ndeed at low risk or whether they could beneﬁt or not from the
ame statin therapy.
∗ Corresponding author. Tel.: +55 61 3442 8439; fax: +55 61 3442 8489.
E-mail address: dclandrei@yahoo.com (A.C. Sposito).
021-9150 © 2010 Elsevier Ireland Ltd. 
oi:10.1016/j.atherosclerosis.2010.10.034
Open access under the Elsevier OA license.f carotid plaques can substantially reduce the CVD risk underestimation.
© 2010 Elsevier Ireland Ltd. 
More to thepoint, can theuse of algorithms,markers of systemic
inﬂammation or assessment of subclinical atherosclerosis mislead
to a low CVD risk stratiﬁcation and preclude patients from pre-
ventive therapies? And if so, how often this occurs? In order to
probe this issue, in this study we assessed how often patients who
are manifesting a myocardial infarction (MI) would not be consid-
ered candidates for intensive lipid-lowering therapy based on the
current approach.
2. Methods
Study subjects were participants in the ongoing Brasilia heart
study described elsewhere [2]. Brieﬂy, in this prospective cohort,
Open access under the Elsevier OA license.355 consecutive patients admitted in the Hospital de Base, Brasília,
Brazil, with ST-segment elevation MI (STEMI) were included in the
study as of May 2006. Inclusion criteria were as follows: (i) less
than 24h after the onset of MI symptoms, (ii) ST-segment eleva-
tion of a least 1mm (frontal plane) or 2mm (horizontal plane) in
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Table 1
Clinical characteristics of enrolled patients.
n 355
Men 75%
Age, years 61±11
Hypertension 58%
Smoking 37%
Sedentary lifestyle 56%
Familial history of coronary disease 36%
Body mass index, kg/m2 26 (24–30)
Waist circumference, cm 96 (91–103)
high risk who are at the present erroneously underestimated and
precluded froman intensive lipid-lowering therapy. In this context,
we observed that more than half the patients with STEMI are not
identiﬁed as high risk by the most well-established clinical algo-
rithms. More serious than this, with the exception of FRS, about
Table 2
CVD risk according to clinical risk score algorithms.
Risk scores CVD risk
Low Intermediate High
FRS, % 9 85 6
RRS, % 52 32 16
PROCAM, % 45 30 25
ASSIGN, % 72 21 8
QRISK, % 41 31 28
SCORE high risk chart, % 59 – 41
SCORE low risk chart, % 59 – 41A.C. Sposito et al. / Athero
wo contiguous leads, and (iii) myocardial necrosis, as evidenced
y increased creatine kinase–MB (CK–MB) and troponin levels. The
tudy was approved by the Institutional Ethics Committee, and all
atients signed an informed consent.
Medical evaluation and blood sampling were performed there-
pon the admission at emergency department. The following
easurements were performed: blood glucose (glucose GOD-
AP, Roche Diagnostics, Mannheim, Germany), total cholesterol
CHOD-PAP, Roche Diagnostics, Mannheim, Germany), triglyc-
rides (GPO-PAP, Roche Diagnostics, Mannheim, Germany), HDL
holesterol (HDL cholesterol without sample pre-treatment, Roche
iagnostics, Mannheim, Germany), CRP (high-sensitivity CRP, Car-
iophase, Dade Behring, Marburg, Germany). LDL cholesterol was
alculated by the Friedewald formula.
The predicted CVD risk was estimated by the Framingham Risk
core (FRS) [3], the Prospective Cardiovascular Münster risk score
PROCAM) [4], the Reynolds risk score [5,6], the Assessing Cardio-
ascular Risk to Scottish Intercollegiate Guidelines Network/SIGN
o Assign Preventative Treatment (ASSIGN) [7], and by the QRE-
EARCH cardiovascular risk algorithm (QRISK) [8,9]. According to
hese algorithms CVD risk was divided into three categories: low
<10%), intermediate (10–20%) and high (>20%) risk for an acute
oronary event within the next 10 years. We also applied the
ystematic COronary Risk Evaluation (SCORE) system from the
uropean Society of Cardiology, which estimates the 10-year risk
f a ﬁrst fatal atherosclerotic event, whether heart attack, stroke,
neurysm of the aorta, or other [10]. For the SCORE, individuals
ith >5% of 10-year risk was considered as high risk [10].
Cardiac computed tomography (CT) and carotid ultrasound
ere performed in the following two weeks after hospital dis-
harge. A 16-channel multidetector CT (1.5mm slice thickness;
rilliance CT, Philips Healthcare, Cleveland, OH, USA) was used
o calculate the coronary artery calcium score (CAC). The carotid
ntima-media thickness (cIMT) and the presence of plaques were
tudied using a high-resolution B-mode ultrasound (Philips, model
E 33, 3–9MHz linear transducer, Philips, Andover, Massachusetts,
SA) and a program of automatic edge detection (QLAB, Advanced
ltrasound Quantiﬁcation Software, Release 7.1, Philips, Bothell,
A) according to the American Society of Echocardiography’s
uidelines [11]. Carotid plaque was deﬁned as the presence of focal
all thickening that is at least 50% greater than that of the sur-
ounding vessel wall or as a focal region with cIMT greater than
.5mm.
Data are presented as mean± standard deviation for normally
istributed data or median (25–75% percentiles) for skewed data.
two-sided p-value of 0.05 was considered statistically signiﬁ-
ant. Statistical analyses were performed using SPSS for Windows
ersion 15.0. The authors had full access to the data and take
esponsibility for its integrity. All authors have read and agree to
he manuscript as written.
. Results
Table 1 shows the clinical characteristics of the study partici-
ants. As Table 2, less than 50% of patients admitted with STEMI
ould be identiﬁed before the event as having high risk by any
f these algorithms. The agreement between the algorithms for
dentifying patients as at high risk was low (kappa 0.11–0.50),
uggesting that the parameters used in these scores can be com-
lementary in identifying risk. In fact, 72% of patients would be
dentiﬁed as high risk by at least one of the seven risk scores. While
he FRS was less equivocal in assigning low risk, other algorithms
ould ascribe it to more than 50% of the enrolled patients.
The time from MI symptoms onset and admission at the emer-
ency department was 211±253min. Thus, in 77% of enrolledCRP, mg/L 0.5 (0.3–1.2)
LDL cholesterol, mg/dL 126±46
HDL cholesterol, mg/dL 39±11
Triglycerides, mg/dL 160±122
patients, blood samples were collected before the raise of CRP that
normally occurs after 6h of MI. In this blood testing, 70% of the
patients had CRP <1.0mg/L. Using CRP≥2mg/L as high risk deﬁning
criterion, only 14% of the patients would be eligible for intensive
lipid-lowering therapy before the coronary event. There was no
correlation between CRP and CAC or cIMT.
In the evaluation after hospital discharge, the average cIMT
was 0.8±0.2mm and only 24% of patients had cIMT ≥1.0mm.
No patient had cIMT above the 75th percentile for his or her age.
Carotid plaques were found in 74% of patients. Adding the pres-
ence of carotid plaque data to the algorithms, a high-risk condition
would be identiﬁed in 75% of patients by FRS, 77% by RRS, 81% by
PROCAM, 80% by QRISK, 88% by ASSIGN and 74% by SCORE.
The CAC ≥100 or ≥400 were found in 66% and 29% of patients,
respectively. However, in 17% of the participants, the reperfusion
treatment was primary angioplasty with stenting. In such cases,
the region bounded to the stent was removed from the analysis
of CAC. As in 34% of these culprit lesions we observed calciﬁcation
in the angiography before stenting, the CAC was underestimated
in 20 cases (5.6%). Adding CAC ≥100 to the algorithms, a high-risk
conditionwould be identiﬁed in 66% of patients by FRS, 68% by RRS,
74% by PROCAM, 76% by QRISK, 92% by ASSIGN and 66% by SCORE.
Adding CAC ≥100 plus the presence of carotid plaque, a high-risk
condition would be identiﬁed in 100% of the patients using any of
the above mentioned algorithms.
4. Discussion
This studywas not designed to validatemethods for detection of
CVD risk, but instead to verify the frequency of individuals at veryFRS: Framingham risk score; RRS: Reynold’s risk score; PROCAM: prospective car-
diovascular Münster risk score; ASSIGN: assessing cardiovascular risk to Scottish
Intercollegiate Guidelines Network/SIGN to assign preventative treatment; QRISK:
QRESEARCH cardiovascular risk algorithm; SCORE: Systematic COronary Risk Eval-
uation.
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alf of these individuals would be identiﬁed as low risk by the all
lgorithms. We also found that the addition of CAC ≥100 and pres-
nce of carotid plaques as high-risk criteria to the algorithmswould
ubstantially reduce the number of patients misclassiﬁed.
It’s countless the number of modiﬁable factors, known and yet
o be discovered, which may accentuate or attenuate the CVD risk.
herefore, it is not surprising that algorithms vary their efﬁcacy in
ifferent populations. Even within the same population, the time
nd change of habits must modify the effectiveness of the algo-
ithms. For example, algorithms developed in the 1970s and 1980s
id not estimate adequately the impact of metabolic syndrome,
n epidemic of today. In some years, the intensity of air pollution
ould become an important variable for the future algorithms [12].
n other words, the set of causes that promote atherogenesis vary
ynamically and, thus, the actual risk canhardly bepredictedby the
ame equation or algorithm in different circumstances, locations or
ver time.
In this study, we tested algorithms among the most frequently
sed around theworld andnoticed that noneof these could identify
s high risk half of patients admitted with STEMI. The low agree-
ent and complementarity between them suggests the possibility
f improving the representativeness and make them useful to a
arger number of individuals. Indeed, new elements such as social
eprivation, family history of CVDandbodymass indexwere added
y the QRISK [8,9] and ASSIGN [7] scores and reduced the number
nidentiﬁed high risk patients in our study.
As noted, low values of plasma CRP and cIMT were found in
hree quarters of the patients enrolled into the study. This ﬁnd-
ng emphasizes the weakness in providing indicators of low risk
n such a complex web of causation such as CVD. In contrast, the
resence of atherosclerotic plaques in carotid or coronary arteries,
he last as estimated by the CAC, was the more frequent ﬁnd-
ng among patients. Naturally, in agreement with other studies
13,14], the diagnosis of the disease overcomes the challenging
f ﬁnding the components of the CVD causal chain and as well
he limitations of the use of indirect unspeciﬁc markers such as
RP.
Some limitations must be considered when interpreting these
ndings. As 23% of patients arrived with more than 6h of symptom
nset, it is possible that a larger number of participants have had
RP <0.1mg/L before the MI. As mentioned above, 17% of patients
ere treated by primary angioplasty with stenting and, therefore,
he region around the stent was systematically removed for anal-
sis of CAC. Thus it is probable that more than 66% of patients
ad CAC ≥100 before the coronary event. In this study, only 5%
f patients enrolled were in prior use of statins and ﬁndings can
e quite distinct in another setting. The CAC, for example, does
ot change signiﬁcantly after treatment with statins, although it
s known that atherogenicity, phenotype and CVD risk change [15].
hus, any extrapolation from these ﬁndings must be carefully con-
idered. Acquisition of CAC and carotid ultrasound was done about
wo weeks after the acute event and, although unlikely, we cannot
ssure you that there has been no progression of the atheroscle-
otic burden in coronary and carotid arteries detectable by these
ethods. Finally, as mentioned above, this study should not beonsidered as a validation of diagnostic methods for cardiovascular
isk. Rather, this serves to drawattention to thedramatic number of
ndividuals currently classiﬁed as having low or intermediate risk
or cardiovascular disease andwhoare consequently deprived of an
ntensive prevention strategy. For the individuals enrolled in this
[
[sis 214 (2011) 148–150
study, assessment of subclinical atherosclerosis would have made
a difference.
In conclusion, the present study showed that based on the cur-
rent strategy for identifying CVD risk, more than half of patients
admittedwithSTEMIwouldnotbe considered candidates for inten-
sive preventive therapy before the event. In addition, consistently
with previous studies, this study suggest that the complementation
of clinical algorithms with of anatomical parameters such as CAC
and the presence of carotid plaques can substantially reduce the
underestimation of CVD risk.
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